Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sibila (Barcelona, Spain), E. Laserna (Mollet del Valles, Spain), A. Shoemark (Dundee, United Kingdom), D. Bilton (London, United Kingdom), M. Crichton (Dundee, United Kingdom), A. De Soyza (Newcastle, United Kingdom), W. Boersma (Alkmaar, Netherlands), J. Altenburg (Amsterdam, Netherlands), J. Chalmers (Dundee, United Kingdom). Heterogeneity of treatment response in bronchiectasis clinical trials. 3332

Member's Comments

No comment yet.

Related content which might interest you: Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 COPD treatment from pathophysiology to clinical trials Source: ERS Live 2007 Year: 2007 The bronchodilator response and clinical characteristics of patients with bronchiectasis Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 The use of induced sputum in clinical trials Source: Eur Respir J 2002; 20: 47S-50S Year: 2002 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial> Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 The effectiveness of different clinical measures in evaluating response to omalizumab Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma Year: 2010 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 Measuring bronchodilation in COPD clinical trials Source: Eur Respir J 2004; 24: Suppl. 48, 122s Year: 2004 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomized controlled trial Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Source: Eur Respir J 2005; 26: 755-758 Year: 2005 A randomised clinical trial to assess the effect of active muscle stimulation on hospitalised patients with COPD exacerbations Source: Annual Congress 2012 - The best posters on physical inactivity, muscle dysfunction and exercise intolerance Year: 2012 Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials Source: International Congress 2017 – COPD management Year: 2017 The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2017 The clear evidence for pulmonary rehabilitation in chronic lung disease - a review of the most important randomised controlled trials Source: International Congress 2018 – PG14 The evolving world of pulmonary rehabilitation Year: 2018 No clinically relevant hypersensitivity reactions in clinical trials with tralokinumab in asthma Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 End-points and biomarkers for clinical trials in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 104-115 Year: 2014